Endometrial Cancer Lymphadenectomy Trial

  • End date
    Feb 15, 2029
  • participants needed
  • sponsor
    Philipps University Marburg Medical Center
Updated on 10 June 2021


The primary aim of this trial is to ascertain whether or not systematic pelvic and para-aortic lymphadenectomy (LNE) does have a significant impact on overall survival (OS) in patients with endometrial cancer (EC) FIGO Stages I or II and high risk of recurrence. Secondary aims will be to evaluate the effect of LNE on disease free survival (DFS) and quality of life, as well as the complications and side effects of LNE and the number of resected lymphnodes. 640 patients with histologically confirmed EC with high risk of recurrence (stage pT1b - pT2, all histological subtypes; pT1a, G3 endometrioid or serous or clear cell EC or carcinosarcomas) will be randomized. In Arm A, a total hysterectomy and bilateral salpingo-oophorectomy and in case of serous or clear cell EC additionally an omentectomy will be performed. In arm B in addition a systematic pelvic and para-aortic LNE up to the level of the left renal vein will be performed.

Condition Cancer of Endometrium Stage I, Cancer of Endometrium Stage II, stage ii endometrial cancer
Treatment Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE)
Clinical Study IdentifierNCT03438474
SponsorPhilipps University Marburg Medical Center
Last Modified on10 June 2021


Yes No Not Sure

Inclusion Criteria

histologically confirmed EC of clinical stages T1b and T2 (all histological types) and stage T1a G3 type 1 (endometrioid, endometriod with squamous differentiation, mucinous) or type 2 tumors (any percentage of serous or clear cell component) or carcinosarcoma
a) no previous surgery concerning EC (primary surgery) or b) surgery after hysterectomy (e.g. for presumed low risk endometrial cancer) is allowed within 8 weeks after hysterectomy if no LNE was performed (secondary surgery)
absence of bulky lymph nodes
performance status ECOG 0-1
age 18 - 75 years
written informed consent
adequate compliance

Exclusion Criteria

stage pT1a, G1 or G2 tumors of type 1 histology
sarcomas (except for carcinosarcoma = malignant mixed Mllerian tumor)
EC of FIGO stages III or IV (except for microscopical lymph node metastases)
evidence of extrauterine disease by visual inspection
recurrent EC
preceding chemo-, radio, or endocrine therapy for EC
any concomitant disease not allowing surgery including lymphadenectomy and/or chemotherapy
any medical history indicating excessive peri-operative risk
any current medication containing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents)
any known disorder or circumstances making participation in trial and follow-up questionable. Insufficient compliance is expected
patients with second malignancies if disease or treatment might have an impact on the patient's prognosis
known HIV-infection or AIDS
simultaneous participation in other clinical trials if not permitted by the steering committee (translational or QoL studies not interfering with the objectives of ECLAT are allowed)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note